Dr. Xingli Wang

So all this is part of our overall strategy of becoming a global player.

Sure.

I mean, there's multifactors coming into it.

You know, why is your original question Hong Kong market sector 70% or US is 5%?

I think this is probably seen relative term.

The Hong Kong or Asian or China related biotech sector was disproportionately suppressed

over the last few years.

So this rebounds more or less in certain proportion was regaining its right positioning rather than only because of the biotech activities, which is coming to the second.

US is always on the high side.

They may be overvalued before.

And on the second aspect or the major driver of the China biotech's output, this has been over the last 10 years.

I would say the China biotech started to become growing, to become established, to become a player like today.

It's accumulation of the time.

Why it comes, you know, you might or Western might say it's all of a sudden.

It's not all of a sudden.

There were two major factors.

The Chinese academic development growth is spanning for the last 40 years.

And that's why the publications in the top journals like Cell Science Nature from Chinese institutions nowadays, number-wise, is similar to U.S.

But that provided a lot of talents.

The second is U.S.